What type of inhibitor does Vandetanib belong to?

Vandetanib (Vandetanib) is a multi-target receptor tyrosine kinase inhibitor. In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of members of the EGFR and VEGFR families, RET, BRK, TIE2, and EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in normal cellular functions and pathological processes, such as tumorigenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.

In vitro, vandetanib inhibits epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells, and inhibits VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. In vivo, vandetanib administration reduced tumor cell-induced angiogenesis, tumor vascular permeability, and inhibited tumor growth and metastasis in mouse models of cancer. Cell culture experiments have shown that the anti-proliferative effect of vandetanib originates from the inhibition of EGFR or VEGFR-2 signaling in endothelial cells, but is related to the inhibition of EGFR signaling in tumor cells. These data demonstrate that at clinically achieved plasma exposures, vandetanib will significantly inhibit VEGFR-2 and EGFR signaling, and that both inhibition of angiogenesis and direct inhibition of tumor cell growth contribute to therapeutic response.

The original drug vandetanib has not yet been marketed in China, so it is not included in medical insurance. The original drug specifications of vandetanib listed overseasThe price of each box of 300mg*30 tablets may be more than 30,000 yuan (the price may fluctuate due to the exchange rate). There is currently no generic drug of vandetanib produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.